Mainz, March 2018 – On March 15th, Prof. Dietmar Zehn from the Technical University of Munich, School of Life Sciences Weihenstephan, will be visiting Mainz in the context of our Seminars in Translational Oncology series (SITO). You are cordially invited to his talk at 5 pm in building 708 of the University Medicine Mainz. The
Author Archive | thomas
Three-year research grant to develop new treatment approaches for neuroendocrine tumors
We are pleased to announce a three-year grant from the Falconwood Foundation, New York, USA, totalling 3 Million Euros. The grant supports the launch of a new research project to identify biomarkers specific for neuroendocrine tumors (NETs) that are crucial for the development of new, personalized immunotherapies to treat NET patients. Further details are announced
TRON is involved in two projects of a new Collaborative Research Center
In the course of evolution, the immune system has developed sophisticated mechanisms to identify and eliminate invading pathogens and degenerate cells, thereby preventing infection and tumor occurrence. When these mechanisms are ineffective or somehow bypassed, tumors or chronic infections may form. Clarifying the processes leading to ineffective immune defense is the central goal of the
Honorary Medical Doctor’s Degree for Cornelis Melief
Mainz, 2017-10-25 – TRON scientific advisor Prof. Dr. Dr. Cornelis J. Melief, Leiden, Netherlands, will be awarded with the degree of an honorary medical doctor. Melief will be awarded for his lifetime achievements as a pioneer of tumor immunology, as well as for his commitment and deserts regarding immunological research in Mainz. Further information about
Neue Krebsimmuntherapien – Ugur Sahin im Expertengespräch
Was versprechen neuartige personalisierte Krebsimmuntherapien? Wie können Patienten von Ihnen profitieren, und welche Risiken bergen die Behandlungen? Zwei neue Ansätze in der Krebsimmuntherapie sind die CAR-T-Methode und die so genannten Neoantigen-Vakzine. Beide werden gerade getestet und sind sehr vielversprechend. Der regionale Radiosender SWR2 sendete hierzu einen Radiobeitrag in seinem Programm. Einen Mitschnitt sowie ein Transkript
Improvement of in vivo expression of genes delivered by self-amplifying RNA using Vaccinia Virus immune evasion proteins
Among nucleic acid-based delivery platforms, self-amplifying RNA (saRNA) vectors are of increasing interest for applications such as transient expression of recombinant proteins and vaccination. Although saRNA is a promising technology, antigen expression from saRNA is limited by the host cells’ innate interferon response. TRON’s Tim Beissert and colleagues show, in an upcoming issue of Human
Individualized cancer immunotherapy
Mainz, September 6, 2017 – Individualized cancer immunotherapy Prof. Ugur Sahin, Managing Director (Science and Research) and Co-Founder of TRON, will talk at the Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in our hometown Mainz. His talk is titled “Individualized Cancer Immunotherapy – Exploring a new landscape” and will cover the implementation of an RNA-based approach
THIRD CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE
Mainz, September 2017 – TRON will also participate at the THIRD CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE in Mainz this year. Meet and talk to our experts in: Bioinformatics: Wednesday, 12:30-2:00 pm Next Generation Sequencing: Wednesday, 3:00-4:00 pm Biomarker: Thursday, 11:30-1:00 pm Immunomonitoring: Thursday, 3:00-4:00 pm Pre-Clinical Research: Friday, 12:30-2:00 pm T-cell Vaccines & Immunotherapy: Friday,
Personalized RNA vaccine induces T cell responses in melanoma
Mainz, July 5th 2017 – Today, TRON and BioNTech AG announced the publication of Phase I clinical trial results in the renowned journal Nature.
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies
Mainz, June 2017 – We are pleased to announce that our close cooperation partner BioNTech has today published an article in Nature Medicine. The paper entitled “Elimination of large tumors in mice by mRNA-encoded bispecific antibodies” reports preclinical data featuring their novel class of mRNA-encoded antibody drugs called RiboMABs® and describes the application of their
